Exposure to contaminated poliovirus vaccine not likely linked to rare cancer

December 31, 2002

The poliovirus vaccine used in mass immunization programs in the late 1950s and early 1960s was contaminated with the monkey virus SV40, which has been detected in some human tumors, particularly pleural mesothelioma. However, the rise in incidence of pleural mesothelioma between 1975 and 1997 is not likely the result of immunization with the SV40-contaminated vaccine, according to an analysis in the January 1 issue of the Journal of the National Cancer Institute.

SV40, or simian virus 40, can cause tumors in rodents when injected at high levels. However, most epidemiologic studies of people who were immunized as children with poliovirus vaccine that was potentially contaminated with SV40 have not found an association between SV40-contaminated poliovirus vaccine and the risk of cancer--even more than 30 years after exposure. Still, the presence of SV40 in some tumors raises the possibility that there may be an association.

To determine whether immunization with the contaminated poliovirus vaccine had any affect on the incidence of pleural mesothelioma, a rare cancer of the membrane that covers the lungs, Howard D. Strickler, M.D., of the Albert Einstein College of Medicine in New York, and his colleagues used cancer incidence data from the National Cancer Institute's Surveillance, Epidemiology, and End Results Program to estimate age- and sex-specific incidence rates of pleural mesothelioma from 1975 through 1997. They then compared trends in mesothelioma incidence with prevalence of exposure to SV40-contaminated poliovirus vaccine.

The authors found that incidence rates increased the most among males who were age 75 or older, the age group least likely to have been exposed to the contaminated poliovirus vaccine. Incidence rates among males in the age groups most heavily exposed to SV40-contaminated poliovirus vaccine (between ages 25 and 54) remained stable or decreased from 1975 through 1997.

Similar trends were seen among females. The authors point out that even though women had similar exposure to SV40 contaminated vaccine, female pleural mesothelioma remained very rare, and the few female cases that did occur were mainly among the elderly who were unlikely to have ever received any poliovirus vaccine. In addition, statistical assessment of trends in pleural mesothelioma incidence did not reveal any increases in rates of the disease that could be attributed to SV40-contaminated poliovirus vaccine in males or females.

"Thus, after almost 40 years of follow-up, U.S. cancer incidence data have not shown an increased incidence of pleural mesothelioma among the birth cohorts that were exposed to SV40-contaminated poliovaccine," the authors conclude. However, they note that "continued surveillance of all vaccine-exposed cohorts is needed, in view of conflicting reports on the detection of SV40 genomic DNA sequences in mesothelioma tumor samples."
-end-
Contact: Abe Habenstreit, Albert Einstein College of Medicine, 718-430-3101; fax: 718-430-3703, habenstr@aecom.yu.edu

Strickler H, Goedert J, Devesa S, Lahey J, Fraumeni J, Rosenberg P. Trends in U.S. pleural mesothelioma incidence rates following simian virus 40 contamination of early poliovirus vaccines. J Natl Cancer Inst 2003;95:38-45.

Note: The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage.

Journal of the National Cancer Institute

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.